The United States has the highest prescription drug prices of any developed nation — by a wide margin. Understanding what Americans actually pay for medications, how that compares to other countries, and what the 2026 pharmaceutical tariff means for future costs is essential context for every patient.
Average Prescription Drug Costs in the US
Based on government data from CMS and the Kaiser Family Foundation:
- Average cost per prescription fill (all drugs): approximately $70–80 including generics
- Average cost per prescription (brand name only): approximately $350–400
- Average cost per prescription (generic only): approximately $35–45
- Average annual drug spend per American: approximately $1,200–$1,500
- Average monthly out-of-pocket cost for patients on multiple brand-name drugs: $300–$600+
These figures are averages — they mask enormous variation. A patient on a single generic blood pressure medication pays $10/month. A patient on a biologic for Crohn's disease may pay $5,000+/month before insurance.
Average Cost by Drug Type
Common generic drugs (monthly):
- Metformin (diabetes): $4–$10
- Lisinopril (blood pressure): $4–$10
- Atorvastatin (cholesterol): $10–$20
- Sertraline (depression): $10–$15
- Levothyroxine (thyroid): $10–$20
Brand name specialty drugs (monthly list price):
- Humira (autoimmune): $7,000–$8,000
- Keytruda (cancer): $15,000–$20,000
- Ozempic (diabetes/weight): $900–$1,000
- Dupixent (atopic dermatitis): $3,500–$4,000
- Eliquis (blood thinner): $550–$650
Most insured patients do not pay list prices — copays and insurance bring out-of-pocket costs down significantly. But uninsured patients and those in high-deductible plans face much higher exposure.
Average Prescription Drug Costs Per Month by Condition
Patients managing chronic conditions often take multiple drugs simultaneously:
- Type 2 diabetes (generic regimen): $30–$60/month
- Type 2 diabetes (brand GLP-1 + insulin): $300–$600/month out of pocket
- Rheumatoid arthritis (generic DMARDs): $20–$50/month
- Rheumatoid arthritis (biologic): $100–$500+/month copay
- HIV (brand name antiretroviral): $50–$200/month copay (Gilead MFN deal covers key drugs)
- Cancer (oral targeted therapy): $200–$1,000+/month copay
Prescription Drug Price Increases Over Time
US drug prices have risen consistently faster than inflation:
- Brand name drug prices increased an average of 4–6% per year over the past decade
- Insulin prices rose over 300% between 2002 and 2013 before legislative price caps
- The CPI for prescription drugs has outpaced general inflation by approximately 2–3x over the past 20 years
The 2026 pharmaceutical tariff represents a potential step-change in this trend for brand name drugs without MFN deals — a 100% tariff could theoretically double acquisition costs overnight for affected drugs.
Why US Drug Prices Are Higher Than Other Countries
Several structural factors drive US drug prices above those in Europe, Japan, and Canada:
1. No central price negotiation — Most other developed countries negotiate drug prices nationally. The US did not do this for most drugs until the Inflation Reduction Act's limited Medicare negotiation provisions (effective 2026 for a small subset of drugs).
2. Patent exclusivity periods — US law provides robust IP protection for drug manufacturers.
3. PBM system complexity — Pharmacy benefit managers negotiate rebates that create opaque pricing structures.
4. Market-based pricing — Drug companies set prices based on what the market will bear, not cost-of-production.
The 2026 tariff's MFN deal mechanism — requiring companies to offer Americans their lowest global prices — is a direct attempt to address this gap, at least for the 13 Annex III companies.
What the Tariff Does to These Averages
For generics (90% of all prescriptions): no change. Fully exempt.
For brand name drugs from MFN deal companies: potential decrease as MFN pricing kicks in, or no change.
For brand name drugs from non-deal companies: potential increase as manufacturers may raise prices in response to tariff costs, or pass costs through the supply chain.
Use the drug search tool to check whether your specific medication is in the exempt, 0% MFN, or at-risk category.